Viabilidad para la implementación de los seguros agricolas por índice climático en Honduras

El seguro agropecuario se presenta como una herramienta de transferencia de riesgo de los productores en asocio con aseguradoras dispuestas a asumir de manera calculada el riesgo de ocurrencia de un siniestro a cambio de una prima. Adicionalmente, el seguro agropecuario vinculado al servicio de crédito podría apoyar a los pequeños productores a acceder a tecnologías apropiadas para la gestión del riesgo climático e incremento de la producción. Sin embargo, en al país aún existe un escaso desarrollo del mercado de seguros agropecuarios, el cual se ha identificado debido a la escasa demanda y oferta. Por el lado de la demanda, la escasez surge de primas elevadas, desconocimiento, falta de cultura del seguro y experiencias negativas. Por el lado de la oferta, se reportan elevados costos operativos y grados de siniestralidad, escaso soporte del gobierno, complejidad de la inspección y falta de información y asesoría. Durante los últimos años, en el país se ha mejorado el marco de políticas del sector agroalimentario a través de la creación de estrategias, planes y políticas que buscan mejorar las intervenciones orientadas a la adaptación y mitigación del cambio climático y la reducción de los riesgos. Este proceso coincide con el de promoción de instrumentos de transferencia del riesgo

Imatinib use in the management of a patient with Doege–Potter syndrome

"Doege–Potter syndrome (DPS) is a paraneoplastic syndrome characterized by nonislet cell tumor hypoglycemia due to a solitary fibrous tumor, which produces insulin-like growth factor II. In this report, we present the case of a 67-year-old male with recurrent and refractory hypoglycemia due to DPS successfully treated with imatinib. He initially presented with neuroglycopenic symptoms and dyspnea secondary to a giant tumor in the left hemithorax, which was totally resected. During follow-up, 7 years later, he presented with thoracoabdominal tumor recurrence associated with severe hypoglycemia and underwent subtotal tumor resection, with a subsequent improvement of symptoms. The following year, he had a recurrence of his intra-abdominal tumor, which was unresectable, associated with severe hypoglycemia refractory to dextrose infusion and corticosteroids, thus receiving imatinib with a favorable response. The clinical presentation, diagnostic approach, progression of the disease, and response to treatment with imatinib in the management of a patient with large, recurrent, and unresectable mesenchymal tumors with insulin-like growth factor-2 secretion causing hypoglycemia highlight the importance of this case report

Yellow fever reemergence in Venezuela – Implications for international travelers and Latin American countries during the COVID-19 pandemic

Fundación Universitaria Autónoma de las Américas. Faculty of Medicine. Grupo de Investigacíon Biomedicina. Pereira, Risaralda, Colombia / Colombian Association of Infectious Diseases. Committe on Tropical Medicine, Zoonoses and Travel Medicine. Bogota, Colombia / Fundación Universitaria Autónoma de las Américas. Grupo de Investigacíon GISCA. Semillero de Zoonosis. Sede Pereira, Pereira, Risaralda, Colombia / Instituto para la Investigación en Ciencias Biomédicas. Emerging Infectious Diseases and Tropical Medicine Research Group. Pereira, Risaralda, Colombia / Pan-American Association of Infectious Diseases. Committe on Travel Medicine. Panama City, Panama / Universidad Cientifica del Sur. Master of Clinical Epidemiology and Biostatistics. Lima, Peru / Institución Universitaria Visión de las Américas. Faculty of Medicine. Grupo de Investigacón Biomedicina. Pereira, Risaralda, Colombia / Institución Universitaria Visión de las Américas. Grupo de Investigación GISCA. Semillero de Zoonosis. Sede Pereira, Pereira, Risaralda, Colombia.Colombian Association of Infectious Diseases. Committe on Tropical Medicine, Zoonoses and Travel Medicine. Bogota, Colombia / Fundación Universitaria Autónoma de las Américas. Grupo de Investigacíon GISCA. Semillero de Zoonosis. Sede Pereira, Pereira, Risaralda, Colombia / Instituto para la Investigación en Ciencias Biomédicas. Emerging Infectious Diseases and Tropical Medicine Research Group. Pereira, Risaralda, Colombia / Institución Universitaria Visión de las Américas. Grupo de Investigación GISCA. Semillero de Zoonosis. Sede Pereira, Pereira, Risaralda, Colombia.Pan-American Association of Infectious Diseases. Committe on Travel Medicine. Panama City, Panama / Instituto Conmemorativo Gorgas de Estudios de la Salud. Clinical Research Deparment. Investigador SNI Senacyt Panama. Panama City, Panama.Pan-American Association of Infectious Diseases. Committe on Travel Medicine. Panama City, Panama / University of Colorado Anschutz Medical Center. Department of Medicine. Division of Infectious Diseases. Aurora, CO, USA / Hospital Infantil de México. Federico Góomez, Méexico City, Mexico.Biomedical Research and Therapeutic Vaccines Institute. Ciudad Bolivar, Venezuela.Colombian Association of Infectious Diseases. Committe on Tropical Medicine, Zoonoses and Travel Medicine. Bogota, Colombia / Universidad de Cordoba. Instituto de Investigaciones Biológicas del Trópico. Colombia.Colombian Association of Infectious Diseases. Committe on Tropical Medicine, Zoonoses and Travel Medicine. Bogota, Colombia / Pan-American Association of Infectious Diseases. Committe on Travel Medicine. Panama City, Panama / Hospital Universitario de Sincelejo. Infectious Diseases and Infection Control Research Group. Sincelejo, Sucre, Colombia / Universidad del Atlático. SUE Caribe. Programa del Doctorado de Medicina Tropical. Barranquilla, Colombia.Colombian Association of Infectious Diseases. Committe on Tropical Medicine, Zoonoses and Travel Medicine. Bogota, Colombia / Universidad Cooperativa de Colombia. Grupo de Investigación en Ciencias Animales. Bucaramanga, Colombia.Fundación Universitaria Autónoma de las Américas. Faculty of Medicine. Grupo de Investigacíon Biomedicina. Pereira, Risaralda, Colombia / Colombian Association of Infectious Diseases. Committe on Tropical Medicine, Zoonoses and Travel Medicine. Bogota, Colombia / Instituto para la Investigación en Ciencias Biomédicas. Emerging Infectious Diseases and Tropical Medicine Research Group. Pereira, Risaralda, Colombia / Pan-American Association of Infectious Diseases. Committe on Travel Medicine. Panama City, Panama / Fundación Universitaria Autónoma de las Américas. Faculty of Medicine. Semillero de Investigación en Infecciones Emergentes y Medicina Tropical. Pereira, Risaralda, Colombia / Institución Universitaria Visión de las Américas. Faculty of Medicine. Grupo de Investigacón Biomedicina. Pereira, Risaralda, Colombia.Instituto Médico La Floresta. Caracas, Venezuela.Universidad del Norte and Hospital Universidad del Norte. Department of Medicine, Health Sciences Division. Barranquilla, Colombia.Pan-American Association of Infectious Diseases. Committe on Travel Medicine. Panama City, Panama / Universidad Central de Venezuela. Faculty of Medicine. Caracas, Venezuela.Institute of Infectious Diseases Emilio Ribas, São Paulo, SP, Brazil.Universidad Estatal del Sur de Manabí. Carrera de Laboratorio Clínico. Cantón Jipijapa, Ecuador.Universidad Católica del Maule. Vicerrectoría de Investigación y Postgrado. Chile.Universidad Central de Venezuela. Faculty of Medicine. Hospital Universitario de Caracas. Department of Internal Medicine. Cardiology Division. Caracas, Venezuela.Hospital José María Vargas. La Guaira, Vargas, Venezuela.Universidad Castilla La Mancha. Facultad de Medicina. Complejo Hospitalario Universitario de Albacete. Servicio de Anatomía Patológica. Albacete, Spain.International Airport Camilo Daza. Health Care Service. Cúcuta, Norte de Santander, Colombia.Universidade de São Paulo. Faculdade de Saúde Pública. Departamento de Epidemiologia. São Paulo, SP, Brazil.Universidad Técnica de Ambato. Ambato, Ecuador.Hospital Transfrontalier Cerdayna. Catalonia, Spain.University of Illinois. Department of Internal Medicine. Division of Infectious Diseases. Chicago, IL, USA.Hospital Evangélico de Montevideo. Montevideo, Uruguay.Universidad Cooperativa de Colombia. Grupo de Investigación en Ciencias Animales. Bucaramanga, Colombia.Instituto Nacional de Salud del Niño San Borja. Infectious Diseases Division. Lima, Peru / Universidad Privada de Tacna. Facultad de Ciencias de la Salud. Tacna, Peru.Hospital Universitario Departamental de Nariño. Pasto, Nariño, Colombia.Universidad de Manizales. School of Medicine. Coordination of Microbiology. Manizales, Caldas, Colombia / Grupo de Resistencia Antibiótica de Manizales. Manizales, Caldas, Colombia.Clínica San Josée. Cúcuta, Norte de Santander, Colombia / Hospital Universitario Erasmo Meoz. Cúcuta, Norte de Santander, Colombia.Hospital de Niños J. M. de Los Ríos. Division of Infectious Diseases. Caracas, Venezuela / Venezuelan Society of Infectious Diseases. Executive Board. Caracas, Venezuela.University of Colorado Anschutz Medical Center. Department of Medicine. Division of Infectious Diseases. Aurora, CO, USA.Universidad Industrial de Santander. Department of Internal Medicine. Bucaramanga, Santander, Colombia.Ministério da Saúde. Secretaria de Vigilância em Saúde. Instituto Evandro Chagas. Ananindeua, PA, Brasil / aq Universidade Federal do Para. Faculdade de Medicina. Belém, PA, Brasil.Hospital de Infecciosas F. Muñíz. Buenos Aires, Argentina.GSK Vaccines. Clinical Research & Development and Medical Affairs. Rio de Janeiro, RJ, Brazil.Hospital de Trauma y Emergencias Federico Abete. Buenos Aires, Argentina.Hospital Británico de Buenos Aires. Buenos Aires, Argentina.Pontificia Universidad Católica de Chile. School of Medicine. Department of Pediatric Infectious Diseases and Immunology. Santiago de Chile, Chile.Hospital de Infecciosas F. Muñíz. Buenos Aires, Argentina.Hospital de Infecciosas F. Muñíz. Buenos Aires, Argentina / Universidad de Buenos Aires. Buenos Aires, Argentina.Latin American Society for Travel Medicine. Panel of Sports and Travel. Buenos Aires, Argentina.Universidad Internacional SEK. Health Sciences Faculty. Research Group of Emerging Diseases, Ecoepidemiology and Biodiversity. Quito, Ecuador / Universidad Central de Venezuela. Facultad de Ciencias. Instituto de Zoología y Ecología Tropical. Caracas, Venezuela.Pan-American Association of Infectious Diseases. Committe on Travel Medicine. Panama City, Panama / Instituto de Investigaciones Biomédicas. Clínica IDB Cabudare. Department of Infectious Diseases and Tropical Medicine. Lara, Venezuela / Venezuelan Science Incubator and the Zoonosis and Emerging Pathogens Regional Collaborative Network. Infectious Diseases Research Branch. Lara, Venezuela / Instituto de Estudios Avanzados. Laboratorio de Señalización Celular y Bioquímica de Parásitos. Caracas, Caracas, Venezuela / Academia Nacional de Medicina. Caracas, Venezuela / The Mount Sinai Hospital-Icahn School of Medicine at Mount Sinai. Department of Pathology, Molecular and Cellbased Medicine. Direction of Microbiology. New York, USA

Clinical and Immunological Factors That Distinguish COVID-19 From Pandemic Influenza A(H1N1).

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), is a global health threat with the potential to cause severe disease manifestations in the lungs. Although COVID-19 has been extensively characterized clinically, the factors distinguishing SARS-CoV-2 from other respiratory viruses are unknown. Here, we compared the clinical, histopathological, and immunological characteristics of patients with COVID-19 and pandemic influenza A(H1N1). We observed a higher frequency of respiratory symptoms, increased tissue injury markers, and a histological pattern of alveolar pneumonia in pandemic influenza A(H1N1) patients. Conversely, dry cough, gastrointestinal symptoms and interstitial lung pathology were observed in COVID-19 cases. Pandemic influenza A(H1N1) was characterized by higher levels of IL-1RA, TNF-α, CCL3, G-CSF, APRIL, sTNF-R1, sTNF-R2, sCD30, and sCD163. Meanwhile, COVID-19 displayed an immune profile distinguished by increased Th1 (IL-12, IFN-γ) and Th2 (IL-4, IL-5, IL-10, IL-13) cytokine levels, along with IL-1β, IL-6, CCL11, VEGF, TWEAK, TSLP, MMP-1, and MMP-3. Our data suggest that SARS-CoV-2 induces a dysbalanced polyfunctional inflammatory response that is different from the immune response against pandemic influenza A(H1N1). Furthermore, we demonstrated the diagnostic potential of some clinical and immune factors to differentiate both diseases. These findings might be relevant for the ongoing and future influenza seasons in the Northern Hemisphere, which are historically unique due to their convergence with the COVID-19 pandemic